CompletedPhase 2NCT03819114
Pharmacokinetic Study to Evaluate Double-Dose Levonorgestrel Emergency Contraception in Combination With Efavirenz-Based Antiretroviral Therapy or Rifampicin-Containing Anti-Tuberculosis Therapy
Studying Primary genito-urinary tuberculosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- Principal Investigator
- Kimberly Scarsi, PharmD, MSNorthwestern University CRS, University of Nebraska Medical Center
- Intervention
- Levonorgestrel (LNG)(drug)
- Enrollment
- 122 target
- Eligibility
- 16 years · FEMALE
- Timeline
- 2019 – 2020
Study locations (18)
- 2701 Northwestern University CRS, Chicago, Illinois, United States
- Rush Univ. Med. Ctr. ACTG CRS (2702), Chicago, Illinois, United States
- Weill Cornell Upton CRS (7803), New York, New York, United States
- Unc Aids Crs (3201), Chapel Hill, North Carolina, United States
- Hosp. of the Univ. of Pennsylvania CRS (6201), Philadelphia, Pennsylvania, United States
- Pitt CRS (1001), Pittsburgh, Pennsylvania, United States
- Trinity Health and Wellness Center CRS (31443), Dallas, Texas, United States
- Gaborone CRS (12701), Gaborone, Botswana
- 12101 Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS, Rio de Janeiro, Brazil
- Kenya Medical Research Institute/Walter Reed Project Clinical Research Center (KEMRI/WRP) CRS (12501), Kericho, Kenya
- Blantyre CRS (30301), Blantyre, Malawi
- Malawi CRS (12001), Lilongwe, Malawi
- University of the Witwatersrand Helen Joseph (WITS HJH) CRS (11101), Johannesburg, Gauteng, South Africa
- Family Clinical Research Unit (FAM-CUR) CRS (8950), Cape Town, West Cape, South Africa
- Durban Adult HIV CRS (11201), Durban, South Africa
- +3 more locations on ClinicalTrials.gov
Collaborators
National Institute of Allergy and Infectious Diseases (NIAID)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03819114 on ClinicalTrials.govOther trials for Primary genito-urinary tuberculosis
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT05917210Peer-led Implementation of TB-HIV Education and Adherence Counseling in UgandaYale University
- RECRUITINGNCT07312266Questioning the Epidemiology of Asymptomatic TBBarcelona Institute for Global Health
- RECRUITINGNANCT05842161South Africa Smoking Cessation and Engagement in HIV/TB Care CareMassachusetts General Hospital
- RECRUITINGPHASE3NCT05575518A Pragmatic Trial With Optimized Dose of Rifampicin and Moxifloxacin for the Treatment of Drug Susceptible Pulmonary TuberculosisStellah Mpagama
- ACTIVE NOT RECRUITINGPHASE4NCT05118490Comparing Treatment Completion Of Daily Rifapentine & Isoniazid For One Month (1HP) To Weekly High Dose Rifapentine & Isoniazid For 3 Months (3HP) In Persons Living With HIV and in Household Contacts of Recently Diagnosed Tuberculosis PatientsThe Aurum Institute NPC
- RECRUITINGNANCT05342064Closing -TB GAPs - for People Living With HIV: TB Guidance for Adaptable Patient-Centered ServiceBaylor College of Medicine